Feasibility Study of SOL (S-1,Oral Leucovorin,and Oxaliplatin) in Patients With Advanced Gastric Cancer

Inclusion Criteria:

* Age over 18 years old
* Histologically or cytologically documented gastric adenocarcinoma
* Performance status (ECOG scale): 0-2
* Life expectancy ≥ 3 months
* No previous treatment(including: radiotherapy,chemotherapy and immunotherapy)
* Prior systemic therapy (for instance, cytotoxic chemotherapy or active/passive immunotherapy) for adjuvant or neoadjuvant treatment for non-metastatic (M0) disease has been completed within 6 months prior to initiation of study treatment.
* WIth Measurable Target lesion
* Patients should sign a written informed consent before study entry

Exclusion Criteria:

* History of hypersensitivity to fluoropyrimidines, S-1, oxaliplatin or the ingredients product
* Inadequate hematopoietic function: WBC≦5,000/mm3; ANC≦2,000/mm3; Platelet≦100,000/mm3
* Inadequate organ function which is defined as below:

Total bilirubin \>2 pper limit of normal range (ULN); ALT / AST \> 2.5 upper limit of normal range (ULN) (\>5.0 x ULN if hepatic metastasis); serum creatinine \> 2 upper limit of normal range (ULN);

* Symptomatic peripheral neuropathy ≥ NCI CTC AE grade 1;
* Receiving a concomitant treatment with other fluoropyrimidines or fluorocytosine;
* Pregnancy or lactation women, or women with suspected pregnancy or men unless using a reliable and appropriate contraceptive method;
* Mental status is not fit for chemotherapy therapy presence of serious concomitant illness which might be aggravated by study medication;
* History of ventricular arrhythmia or congestive heart failure;
* Active cardiac disease e.g. decompensate myocardial infarction within the 6-month period preceding entry into the study;
* Significant co-morbid medical conditions, including, but not limited to, Chronic obstructive pulmonary disease, interstitial pneumonia ,pulmonary heart failure, renal failure, hepatic failure, haemorrhagic peptic ulcer, mechanical, paralytic or poor control diabetes